If you've ever wanted to integrate OpenAI's ChatGPT features into your Java programs, you'll be happy to learn that Spring AI has made the process easier than ever. And it's not just easier to connect ...

Companies are scrambling to deal with the glut. Credit...Mojo Wang Supported by By Mike Isaac and Erin Griffith Reporting from San Francisco When a financial services company recently began using ...

Nearly 2,000 internal files were briefly leaked after ‘human error’, raising fresh security questions at the AI company Anthropic accidentally released part of the internal source code for its ...

Anthropic accidentally leaked part of the internal source code for its coding assistant Claude Code, according to a spokesperson. The leak could help give software developers, and Anthropic's ...

The Java ecosystem has historically been blessed with great IDEs to work with, including NetBeans, Eclipse and IntelliJ from JetBrains. However, in recent years Microsoft's Visual Studio Code editor ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...